# Real-world analysis of teclistamab in 123 RRMM patients from Germany

*PRI Rank #6 · Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026*

*Canonical URL: https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026/rank-6*

| Field | Value |
| --- | --- |
| Rank | #6 |
| 18m citations | 59 |
| Journal | Leukemia |
| Year | 2024 |
| DOI | 10.1038/s41375-024-02154-5 |
| Corresponding authors | Leo Rasche |
| Institution | University Hospital of Würzburg, Germany |

**Ranking page:** [Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026](https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026)

**Paper link:** [10.1038/s41375-024-02154-5](https://doi.org/10.1038/s41375-024-02154-5)

## Topics

teclistamab · BCMA-CD3 bispecific antibody · MajesTEC-1 · Relapsed/refractory multiple myeloma · Triple-class refractory multiple myeloma · Penta-drug refractory multiple myeloma · prior BCMA-directed therapy · idecabtagene vicleucel · CAR T-cell therapy · Objective response rate · Progression-free survival · Extramedullary disease · ISS stage III · Duration of response · BCMA-naive patients · cytopenias · infections as adverse events · Real-world evidence · German multicenter cohort · Retrospective analysis

## Cite this ranking

```
Pepkio Research Index (PRI). Topics and Trends in Most Cited Monoclonal and Polyclonal Antibodies Research Papers, Class of 2026. https://pri.pepkio.com/top-papers/monoclonal-and-polyclonal-antibodies-research/2026. Accessed 2026-07-15.

Zheng Su, Tinsley Li, Thematic Shifts in Early-High-Impact Cancer Genomics and Diagnostics Research: A Bibliometric and Semantic Analysis. bioRxiv 2026.07.04.736459; doi: https://doi.org/10.64898/2026.07.04.736459
```